WallStSmart

Merck & Company Inc (MRK)vsInspireMD Inc (NSPR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 606168% more annual revenue ($65.77B vs $10.85M). MRK leads profitability with a 13.6% profit margin vs 0.0%. MRK earns a higher WallStSmart Score of 50/100 (D+).

MRK

Hold

50

out of 100

Grade: D+

Growth: 3.3Profit: 8.0Value: 2.7Quality: 5.0
Piotroski: 3/9Altman Z: 2.30

NSPR

Hold

41

out of 100

Grade: D

Growth: 8.0Profit: 2.5Value: 6.7Quality: 6.5
Piotroski: 3/9Altman Z: -5.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MRKSignificantly Overvalued (-49.3%)

Margin of Safety

-49.3%

Fair Value

$80.88

Current Price

$120.79

$39.91 premium

UndervaluedFair: $80.88Overvalued
NSPRUndervalued (+47.1%)

Margin of Safety

+47.1%

Fair Value

$3.26

Current Price

$0.93

$2.33 discount

UndervaluedFair: $3.26Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MRK3 strengths · Avg: 9.3/10
Market CapQuality
$285.64B10/10

Mega-cap, among the largest globally

Operating MarginProfitability
38.6%10/10

Strong operational efficiency at 38.6%

Free Cash FlowQuality
$2.93B8/10

Generating 2.9B in free cash flow

NSPR3 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
122.2%10/10

Revenue surging 122.2% year-over-year

Debt/EquityHealth
0.0510/10

Conservative balance sheet, low leverage

Areas to Watch

MRK4 concerns · Avg: 3.5/10
P/E RatioValuation
32.6x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Debt/EquityHealth
1.073/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

NSPR4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$35.85M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.

Bull Case : NSPR

The strongest argument for NSPR centers on Price/Book, Revenue Growth, Debt/Equity. Revenue growth of 122.2% demonstrates continued momentum.

Bear Case : MRK

The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.

Bear Case : NSPR

The primary concerns for NSPR are EPS Growth, Market Cap, Profit Margin.

Key Dynamics to Monitor

MRK profiles as a value stock while NSPR is a hypergrowth play — different risk/reward profiles.

NSPR carries more volatility with a beta of 0.74 — expect wider price swings.

NSPR is growing revenue faster at 122.2% — sustainability is the question.

MRK generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (50/100 vs 41/100). NSPR offers better value entry with a 47.1% margin of safety. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

InspireMD Inc

HEALTHCARE · MEDICAL DEVICES · USA

InspireMD, Inc., a medical device company, is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular disease in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.

Want to dig deeper into these stocks?